Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia

Published:2021-05-28 Issue:8 Volume:96 Page:1000-1007
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Jain Nitin¹^ORCID,Maiti Abhishek¹^ORCID,Ravandi Farhad¹^ORCID,Konopleva Marina¹^ORCID,Daver Naval¹^ORCID,Kadia Tapan¹^ORCID,Pemmaraju Naveen¹^ORCID,Short Nicholas¹^ORCID,Kebriaei Partow²,Ning Jing³,Cortes Jorge⁴^ORCID,Jabbour Elias¹^ORCID,Kantarjian Hagop¹

Affiliation:

1. Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA

2. Department of Stem Cell Transplantation and Cellular Therapy The University of Texas MD Anderson Cancer Center Houston Texas USA

3. Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston Texas USA

4. Georgia Cancer Center Augusta University Augusta Georgia

Funder

National Institutes of Health

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26238

Reference22 articles.

1. How I treat Philadelphia chromosome–positive acute lymphoblastic leukemia

2. US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL

3. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study

4. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

5. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Critical review of clinical data and expert-based recommendations for the use of bosutinib in the treatment of chronic myeloid leukemia;Frontiers in Oncology;2024-08-26

2. Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions;Cancer;2024-08-02

3. Olverembatinib combined with inotuzumab ozogamicin in relapsed refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: A case report;Medicine;2024-07-19

4. Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions;Leukemia;2024-06-20

5. Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions;Journal of Hematology & Oncology;2024-05-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3